WUXI BIO (02269) YINGXI: Shareholders' net profit in 2025 increased by 46.3% year-on-year.

WUXI BIO (02269) announced that the group is expected to achieve a revenue growth of approximately 16.7% in the 2025 fiscal year, reaching RMB 21.79 billion; the gross profit margin is expected to increase by about 5 percentage points to 46% year-on-year; adjusted gross profit is expected to grow by 25.5% year-on-year, reaching approximately RMB 10.638 billion. Profit and profits attributable to equity shareholders of the company are expected to increase by approximately 45.3% to RMB 5.733 billion and approximately 46.3% to RMB 4.908 billion, respectively; adjusted net profit is expected to increase by approximately 22% to RMB 6.586 billion year-on-year. The announcement stated that the revenue growth of WUXI BIO is attributed to the successful execution of the "Follow and Win Molecules" strategy, as well as leading technology platforms, industry-best project delivery times, and outstanding project execution track record. In 2025, WUXI BIO's integrated CRDMO platform added 209 new comprehensive projects throughout the year, reaching a total of 945 projects, setting a new record. In the announcement, WUXI BIO mentioned that based on rapidly developing technology platforms such as bispecific antibodies and ADCs (Antibody-Drug Conjugates), it has expanded its range of services to the biopharmaceutical industry, including research discovery, pre-IND development, and clinical and commercial production. According to the announcement, other reasons for the performance growth of WUXI BIO include: revenue growth from research services generated by multiple advanced technologies in the group; utilization of existing and new capacities, including the ramp-up of production capacity at the European production base; cost savings and efficiency improvements through lean operation management systems and digital solutions, and investment gains through portfolio investments.